

CRYO CELL INTERNATIONAL INC

Form 10-Q

April 15, 2013

Table of Contents

## U.S. SECURITIES AND EXCHANGE COMMISSION

WASHINGTON D.C. 20549

### FORM 10-Q

(Mark One)

**Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.**  
For the quarterly period ended February 28, 2013

**Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.**  
For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission File Number 0-23386

## CRYO-CELL INTERNATIONAL, INC.

(Exact name of Registrant as Specified in its Charter)

DELAWARE

22-3023093

Edgar Filing: CRYO CELL INTERNATIONAL INC - Form 10-Q

(State or other Jurisdiction of

(I.R.S. Employer

Incorporation or Organization)

Identification No.)

700 Brooker Creek Blvd. Oldsmar, FL 34677

(Address of Principal Executive Offices) (Zip Code)

Issuer's phone number, including area code: (813) 749-2100

(Former name, former address and former fiscal year, if changed since last report).

Check whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  No  Not Applicable

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definition of large accelerated filer, accelerated filer and small reporting company in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

State the number of shares outstanding of each of the Registrant's classes of common stock, as of the latest practicable date.

As of April 8, 2013, 11,860,040 shares of \$0.01 par value common stock were issued and 10,960,538 were outstanding.

**Table of Contents**

**CRYO-CELL INTERNATIONAL, INC. AND SUBSIDIARIES**

**TABLE OF CONTENTS**

	<b>PAGE</b>
<b>PART I - FINANCIAL INFORMATION (UNAUDITED)</b>	
<b>Item 1. Financial Statements</b>	
<u>Consolidated Balance Sheets</u>	3
<u>Consolidated Statements of Operations</u>	4
<u>Consolidated Statements of Cash Flows</u>	5
<u>Notes to Consolidated Financial Statements</u>	6
<b><u>Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</u></b>	21
<b><u>Item 3. Quantitative and Qualitative Disclosures about Market Risk</u></b>	28
<b><u>Item 4. Controls and Procedures</u></b>	28
<b>PART II - OTHER INFORMATION</b>	
<b><u>Item 1. Legal Proceedings</u></b>	29
<b><u>Item 1A. Risk Factors</u></b>	30
<b><u>Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</u></b>	31
<b><u>Item 3. Defaults Upon Senior Securities</u></b>	31
<b><u>Item 4. Mine Safety Disclosures</u></b>	31
<b><u>Item 5. Other Information</u></b>	31
<b><u>Item 6. Exhibits</u></b>	32
<b><u>SIGNATURES</u></b>	33

**Table of Contents****CRYO-CELL INTERNATIONAL, INC. AND SUBSIDIARIES**

## CONSOLIDATED BALANCE SHEETS

	February 28, 2013 (unaudited)	November 30, 2012
<b><u>ASSETS</u></b>		
<b><u>Current Assets</u></b>		
Cash and cash equivalents	\$ 2,859,056	\$ 2,677,382
Restricted cash	2,548,125	2,576,844
Accounts receivable (net of allowance for doubtful accounts of \$1,471,430 and \$1,367,465, respectively)	3,358,171	3,401,597
Prepaid expenses and other current assets	550,575	659,179
<b>Total current assets</b>	<b>9,315,927</b>	<b>9,315,002</b>
<b><u>Property and Equipment-net</u></b>	<b>1,259,958</b>	<b>1,281,075</b>
<b><u>Other Assets</u></b>		
Marketable securities and other investments	14,040	13,660
Investment in Saneron CCEL Therapeutics, Inc.	684,000	684,000
Long-term note receivable, net of current portion	405,696	550,697
Deposits and other assets, net	499,852	486,225
<b>Total other assets</b>	<b>1,603,588</b>	<b>1,734,582</b>
<b>Total assets</b>	<b>\$ 12,179,473</b>	<b>\$ 12,330,659</b>
<b><u>LIABILITIES AND STOCKHOLDERS DEFICIT</u></b>		
<b><u>Current Liabilities</u></b>		
Accounts payable	\$ 1,444,967	\$ 1,209,973
Accrued expenses	2,597,357	2,917,758
Deferred revenue	6,367,593	6,536,160
<b>Total current liabilities</b>	<b>10,409,917</b>	<b>10,663,891</b>
<b><u>Other Liabilities</u></b>		
Deferred revenue, net of current portion	8,341,962	8,364,533
Long-term liability - revenue sharing agreements	2,300,000	2,300,000
<b>Total other liabilities</b>	<b>10,641,962</b>	<b>10,664,533</b>
Commitments and Contingencies (Note 7)		
<b><u>Stockholders Deficit</u></b>		
Preferred stock (\$.01 par value, 500,000 authorized and none issued)		
Common stock (\$.01 par value, 20,000,000 authorized; 11,860,040 issued and 10,960,538 outstanding as of February 28, 2013 and 11,860,040 issued and 11,067,666 outstanding as of November 30, 2012)	118,600	118,600
Additional paid-in capital	26,952,876	26,824,478
Treasury stock, at cost	(2,434,550)	(2,187,505)

Edgar Filing: CRYO CELL INTERNATIONAL INC - Form 10-Q

Accumulated deficit	(33,509,332)	(33,753,338)
Total stockholders' deficit	(8,872,406)	(8,997,765)
Total liabilities and stockholders' deficit	\$ 12,179,473	\$ 12,330,659

The accompanying notes are an integral part of these consolidated financial statements.

**Table of Contents****CRYO-CELL INTERNATIONAL, INC. AND SUBSIDIARIES**

## CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

	For the Three Months Ended	
	February 28, 2013	February 29, 2012
<b>Revenue:</b>		
Processing and storage fees	\$ 4,276,553	\$ 3,836,847
Licensee income	323,534	341,742
Total revenue	4,600,087	4,178,589
<b>Costs and Expenses:</b>		
Cost of sales	1,279,813	1,026,903
Selling, general and administrative expenses	2,695,278	3,160,797
Research, development and related engineering	10,921	14,579
Depreciation and amortization	51,014	56,255
Total costs and expenses	4,037,026	4,258,534
<b>Operating Income (Loss)</b>	<b>563,061</b>	<b>(79,945)</b>
<b>Other Income (Expense):</b>		
Other income	12,257	20,414
Extinguishment of revenue sharing agreements		(1,227,390)
Interest expense	(250,538)	(299,165)
Total other expense	(238,281)	(1,506,141)
Income (Loss) before equity in losses of affiliate and income tax expense	324,780	(1,586,086)
Equity in losses of affiliate	(38,450)	(38,832)
Income (Loss) before income tax expense	286,330	(1,624,918)
Income tax expense	(42,324)	(57,145)
<b>Net Income (Loss)</b>	<b>\$ 244,006</b>	<b>\$ (1,682,063)</b>
Net income (loss) per common share - basic	\$ 0.02	\$ (0.15)
Weighted average common shares outstanding - basic	10,982,389	11,488,980
Net income (loss) per common share - diluted	\$ 0.02	\$ (0.15)

Edgar Filing: CRYO CELL INTERNATIONAL INC - Form 10-Q

Weighted average common shares outstanding - diluted	11,105,094	11,488,980
--	------------	------------

The accompanying notes are an integral part of these consolidated financial statements.

**Table of Contents****CRYO-CELL INTERNATIONAL, INC. AND SUBSIDIARIES**

## CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	For the Three Months Ended	
	February 28, 2013	February 29, 2012
<b>Cash flows from operating activities:</b>		
Net income (loss)	\$ 244,006	\$ (1,682,063)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:		
Depreciation and amortization expense	104,786	110,204
Compensatory element of stock options	89,948	259,421
Provision for doubtful accounts	86,135	135,491
Equity in losses of affiliate	38,450	38,832
Loss on extinguishment of revenue sharing agreements		1,227,390
Changes in assets and liabilities:		
Accounts and notes receivable	102,292	(142,967)
Prepaid expenses and other current assets	108,604	(24,747)
Deposits and other assets, net	7,999	5,000
Accounts payable	234,994	402,304
Accrued expenses	(320,401)	93,264
Deferred consulting obligation		(26,705)
Deferred revenue	(191,138)	(237,517)
<b>Net cash provided by operating activities</b>	<b>505,675</b>	<b>157,907</b>
<b>Cash flows from investing activities:</b>		
Restricted cash held in escrow	28,719	
Purchases of property and equipment	(77,293)	(79,241)
Proceeds from sale of marketable securities and other investments		1,002,000
Investments in patents	(28,382)	(12,177)
<b>Net cash (used in) provided by investing activities</b>	<b>(76,956)</b>	<b>910,582</b>
<b>Cash flows from financing activities:</b>		
Long-term liability-revenue sharing agreements		(2,300,000)
Treasury stock purchases	(247,045)	(753,511)
<b>Net cash used in financing activities</b>	<b>(247,045)</b>	<b>(3,053,511)</b>
<b>Increase (decrease) in cash and cash equivalents</b>	<b>181,674</b>	<b>(1,985,022)</b>
Cash and cash equivalents - beginning of period	2,677,382	6,305,095
Cash and cash equivalents - end of period	\$ 2,859,056	\$ 4,320,073

The accompanying notes are an integral part of these consolidated financial statements.



**Table of Contents**

**CRYO-CELL INTERNATIONAL, INC. AND SUBSIDIARIES**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**February 28, 2013**

**(Unaudited)**

**Note 1 Basis of Presentation and Significant Accounting Policies**

The unaudited consolidated financial statements including the Consolidated Balance Sheets as of February 28, 2013 and November 30, 2012 and the related Consolidated Statements of Operations and Cash Flows for the three months ended February 28, 2013 and February 29, 2012 have been prepared by Cryo-Cell International, Inc. and its subsidiaries ( the Company or Cryo-Cell ) pursuant to the rules and regulations of the Securities and Exchange Commission for interim financial reporting. Certain financial information and note disclosures, which are normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America, have been condensed or omitted pursuant to those rules and regulations. It is suggested that these consolidated financial statements be read in conjunction with the financial statements and notes thereto included in the Company's November 30, 2012 Annual Report on Form 10-K. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations, and changes in cash flows for all periods presented have been made. The results of operations for the three months ended February 28, 2013 are not necessarily indicative of the results expected for any interim period in the future or the fiscal year ending November 30, 2013.

**Revenue Recognition**

*Revenue Recognition for Arrangements with Multiple Deliverables*

For multi-element arrangements, the Company allocates revenue to all deliverables based on their relative selling prices. In such circumstances, accounting principles establish a hierarchy to determine the selling price to be used for allocating revenue to deliverables as follows: (i) vendor-specific objective evidence of fair value ( VSOE ), (ii) third-party evidence of selling price ( TPE ), and (iii) best estimate of the selling price ( ESP ). VSOE generally exists only when the Company sells the deliverable separately and it is the price actually charged by the Company for that deliverable.

The Company has identified two deliverables generally contained in the arrangements involving the sale of its umbilical cord blood product. The first deliverable is the processing of a specimen. The second deliverable is either the annual storage of a specimen or the 21 year storage fee charged for a specimen. The Company has allocated revenue between these deliverables using the relative selling price method. The Company has VSOE for its annual storage fees as the Company renews storage fees annually with its customers on a standalone basis. Because the Company has neither VSOE nor TPE for the processing and 21 year storage deliverables, the allocation of revenue has been based on the Company's ESPs. Amounts allocated to processing a specimen are recognized at the time of sale. Amounts allocated to the storage of a specimen are recognized ratably over the contractual storage period. Any discounts given to the customer are recognized by applying the relative selling price method whereby after the Company determines the selling price to be allocated to each deliverable (processing and storage), the sum of the prices of the deliverables is then compared to the arrangement consideration, and any difference is applied to the separate deliverables ratably.

The Company's process for determining its ESP for deliverables without VSOE or TPE considers multiple factors that may vary depending upon the unique facts and circumstances related to each deliverable. Key factors considered by the Company in developing the ESPs for its processing and 21 year storage fee include the Company's historical pricing practices as well as expected profit margins.

## **Table of Contents**

The Company records revenue from processing and storage of specimens and pursuant to agreements with licensees. The Company recognizes revenue from processing fees upon completion of processing and recognizes storage fees ratably over the contractual storage period, as well as, other income from royalties paid by licensees related to long-term storage contracts which the Company has under license agreements. Contracted storage periods can range from one to twenty-one years. Deferred revenue on the accompanying consolidated balance sheets includes the portion of the annual storage fee and the twenty-one year storage fee that is being recognized over the contractual storage period as well as royalties received from foreign licensees related to long-term storage contracts in which the Company has future obligations under the license agreement. The Company classifies deferred revenue as current if the Company expects to recognize the related revenue over the next 12 months. The Company also records revenue within processing and storage fees from shipping and handling billed to customers when earned. Shipping and handling costs that the Company incurs are expensed and included in cost of sales.

The Company has not had a third party conduct a physical inventory count of all specimens stored; however, the Company from time to time will perform a physical inventory count of specimens stored to ensure that all records are accurate.

## **Income Taxes**

Deferred income tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred income tax assets and liabilities are measured using enacted tax rates expected to be recovered or settled. The Company has recorded a valuation allowance of \$10,812,000 and \$10,947,000 as of February 28, 2013 and November 30, 2012, respectively, as the Company does not believe it is more likely than not that all future income tax benefits will be realized. When the Company changes its determination as to the amount of deferred income tax assets that can be realized, the valuation allowance is adjusted with a corresponding impact to income tax expense in the period in which such determination is made. The ultimate realization of the Company's deferred income tax assets depends upon generating sufficient taxable income prior to the expiration of the tax attributes. In assessing the need for a valuation allowance, the Company projects future levels of taxable income. This assessment requires significant judgment. The Company examines the evidence related to the recent history of income or losses, the economic conditions in which the Company operates and forecasts and projections to make that determination.

There was no U.S. income tax expense for the three months ended February 28, 2013 and February 29, 2012 due to the utilization of net operating losses and foreign tax credit carryforwards, which were not previously benefited in the Company's financial statements.

The Company records foreign income taxes withheld from installment payments of non-refundable up-front license fees and royalty income earned on the processing and storage of cord blood stem cell specimens in geographic areas where the Company has license agreements. The Company recognized approximately \$42,000 and \$57,000 for the three months ended February 28, 2013 and February 29, 2012, respectively, of foreign income tax expense. Foreign income tax expense is included in income tax expense in the accompanying consolidated statements of operations.

The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements

## **Table of Contents**

is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. Increases or decreases to the unrecognized tax benefits could result from management's belief that a position can or cannot be sustained upon examination based on subsequent information or potential lapse of the applicable statute of limitation for certain tax positions.

The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. For the three months ended February 28, 2013 and February 29, 2012, the Company had no provisions for interest or penalties related to uncertain tax positions.

## **Long-Lived Assets**

The Company evaluates the realizability of its long-lived assets, which requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment, such as reductions in demand or when significant economic slowdowns are present. Reviews are performed to determine whether the carrying value of an asset is impaired, based on comparisons to undiscounted expected future cash flows. If this comparison indicates that there is impairment and carrying value is in excess of fair value, the impaired asset is written down to fair value, which is typically calculated using: (i) quoted market prices or (ii) discounted expected future cash flows utilizing a discount rate. The Company did not note any impairment for the three months ended February 28, 2013.

## **Stock Compensation**

As of February 28, 2013, the Company has three stock-based compensation plans, which are described in Note 4. The Company recognized approximately \$90,000 and \$259,000 for the three months ended February 28, 2013 and February 29, 2012, respectively, of stock compensation expense.

The Company recognizes stock-based compensation based on the fair value of the related awards. Under the fair value recognition guidance of stock-based compensation accounting rules, stock-based compensation expense is estimated at the grant date based on the fair value of the award and is recognized as expense over the requisite service period of the award. The fair value of service-based vesting condition and performance-based vesting condition stock option awards is determined using the Black-Scholes valuation model. The Company estimates the fair value of stock option awards as of the grant date by applying the Black-Scholes option pricing model. For stock option awards with only service-based vesting conditions and graded vesting features, the Company recognizes stock compensation expense based on the graded-vesting method. To value awards with market-based vesting conditions the Company uses a binomial valuation model. The Company recognizes compensation cost for awards with market-based vesting conditions on a graded-vesting basis over the derived service period. The use of these valuation models involve assumptions that are judgmental and highly sensitive in the determination of compensation expense and include the expected life of the option, stock price volatility, risk-free interest rate, dividend yield, exercise price, and forfeiture rate. Forfeitures are estimated at the time of valuation and reduce expense ratably over the vesting period.

The estimation of stock awards that will ultimately vest requires judgment and to the extent that actual results or updated estimates differ from current estimates, such amounts will be recorded as a cumulative adjustment in the period they become known. The Company considered many factors when estimating forfeitures, including the recipient groups and historical experience. Actual results and future changes in estimates may differ substantially from current estimates.

The Company issues performance-based equity awards which vest upon the achievement of certain financial performance goals, including revenue and income targets. Determining the appropriate

## **Table of Contents**

amount to expense based on the anticipated achievement of the stated goals requires judgment, including forecasting future financial results. The estimate of the timing of the expense recognition is revised periodically based on the probability of achieving the required performance targets and adjustments are made as appropriate. The cumulative impact of any revision is reflected in the period of the change. If the financial performance goals are not met, the award does not vest, so no compensation cost is recognized and any previously recognized stock-based compensation expense is reversed.

The Company issues equity awards with market-based vesting conditions which vest upon the achievement of certain stock price targets. If the awards are forfeited prior to the completion of the derived service period, any recognized compensation is reversed. If the awards are forfeited after the completion of the derived service period, the compensation cost is not reversed, even if the awards never vest.

## **Fair Value of Financial Instruments**

Management uses a fair value hierarchy, which gives the highest priority to quoted prices in active markets. The fair value of financial instruments is estimated based on market trading information, where available. Absent published market values for an instrument or other assets, management uses observable market data to arrive at its estimates of fair value. Management believes that the carrying amount of cash and cash equivalents, accounts receivable, notes receivable, accounts payable and accrued expenses approximate fair value. The Company believes that the fair value of its revenue sharing agreement's liability recorded on the balance sheet is between the recorded book value and up to the Company's recent settlement experience as discussed in Note 8, due to the various terms and conditions associated with each Revenue Sharing Agreement.

The Company uses an accounting standard that defines fair value as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the standard establishes a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. The three levels of inputs used to measure fair value are as follows:

- Level 1 Quoted prices in active markets for identical assets or liabilities.
- Level 2 Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.
- Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs.

**Table of Contents**

The following table summarizes the financial assets and liabilities measured at fair value on a recurring basis as of February 28, 2013 and November 30, 2012, respectively, segregated among the appropriate levels within the fair value hierarchy:

Description	Fair Value at	Fair Value Measurements		
	February 28, 2013	at February 28, 2013 Using		
		Level 1	Level 2	Level 3
<b>Assets:</b>				
Trading Securities	\$ 14,040	\$ 14,040		

Description	Fair Value at	Fair Value Measurements		
	November 30, 2012	at November 30, 2012 Using		
		Level 1	Level 2	Level 3
<b>Assets:</b>				
Trading Securities	\$ 13,660	\$ 13,660		

The following is a description of the valuation techniques used for these items, as well as the general classification of such items pursuant to the fair value hierarchy:

*Trading securities* The Company purchased trading securities of \$20,760 during the year ended November 30, 2012. None were purchased during the quarter ended February 28, 2013. Fair values for these investments are based on quoted prices in active markets and are therefore classified within Level 1 of the fair value hierarchy.

The Company is permitted to make an election to carry certain eligible financial assets and liabilities at fair value, even if fair value measurement has not historically been required for such assets and liabilities under U.S. GAAP. The Company made no elections to record any such assets and or liabilities at fair value.

**Product Warranty and Cryo-Cell Cares™ Program**

In December 2005, the Company began providing its customers that enrolled after December 2005 a payment warranty under which the Company agrees to pay \$50,000 to its client if the umbilical cord blood product retrieved is used for a stem cell transplant for the donor or an immediate family member and fails to engraft, subject to various restrictions. Effective February 1, 2012, the Company increased the \$50,000 payment warranty to a \$75,000 payment warranty to all of its new clients. Additionally, under the Cryo-Cell Cares™ program, the Company will pay \$10,000 to the client to offset personal expenses if the umbilical cord blood product is used for bone marrow reconstitution in a myeloblastic transplant procedure. The product warranty and the Cryo-Cell Cares program are available to clients who enroll under this structure for as long as the specimen is stored with the Company. The Company has not experienced any claims under the warranty program nor has it incurred costs related to these warranties. The Company does not maintain insurance for this warranty program and therefore maintains reserves to cover any estimated potential liabilities. The Company's reserve balance is based on the \$75,000 or \$50,000 (as applicable) maximum payment and the \$10,000 maximum expense reimbursement multiplied by formulas to determine the projected number of units requiring a payout. The Company determined the estimated expected usage and engraftment failure rates based on an analysis of the historical usage and failure rates and the historical usage and failure rates in other private and public cord blood banks based on published data. The Company's estimates of expected usage and engraftment failure could change as a result of changes in actual usage rates or failure rates and such changes would require an adjustment to the established reserves. The historical usage and failure rates have been very low and a small increase in the number of transplants or engraftment failures could cause a significant increase in the estimated rates used in determining the Company's reserve. In addition, the reserve will increase as additional umbilical cord blood specimens are stored which are subject to the warranty. As of February 28, 2013 and November 30, 2012 the Company recorded reserves under these programs in the amounts of \$14,756 and \$14,485, respectively, which are included in accrued expenses in the accompanying consolidated balance sheets.

**Table of Contents****Recently Issued Accounting Pronouncements**

In February 2013, the FASB issued Accounting Standards Update No. 2013-02, *Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income* ( ASU 2013-02 ). This update will require companies to present information about amounts reclassified out of accumulated other comprehensive income and their corresponding effect on net income in one place and reference the amounts to the related footnote disclosures. Current accounting standards present this information in different places throughout the financial statements. ASU 2013-02 is effective for interim and annual periods beginning after December 15, 2012, with early adoption permitted. The adoption of ASU 2013-02 will only impact disclosure requirements and will not have any effect on the Company's consolidated financial statements or on its financial condition.

**Note 2 Income (Loss) per Common Share**

Net income (loss) per common share data are based on net income (loss). The following table sets forth the calculation of basic and diluted earnings (loss) per share:

	For the three months ended February 28, 2013	For the three months ended February 29, 2012
<b>Numerator:</b>		
Net Income (Loss)	\$ 244,006	(\$ 1,682,063)
<b>Denominator:</b>		
Weighted-average shares outstanding-basic	10,982,389	11,488,980
Dilutive common shares issuable upon exercise of stock options	122,705	
Weighted-average shares-diluted	11,105,094	11,488,980
<b>Earnings (Loss) per share:</b>		
Basic	\$ 0.02	(\$ 0.15)
Diluted	\$ 0.02	(\$ 0.15)

## **Table of Contents**

For the three months ended February 28, 2013, the Company excluded the effect of 510,589 outstanding options from the computation of diluted earnings per share, as the effect of potentially dilutive shares from the outstanding stock options would be anti-dilutive. For the three months ended February 29, 2012, the Company excluded the effect of all outstanding stock options from the computation of diluted earnings per share, as the effect of potentially dilutive shares would be anti-dilutive.

### **Note 3 Investment in Saneron CCEL Therapeutics, Inc. ( Saneron )**

As of February 28, 2013 and November 30, 2012, the Company had an ownership interest of approximately 34% in Saneron, which is accounted for under the equity method of accounting. During 2006, the Company ceased recording its share of Saneron's losses once the investment balance was written down to the total amount of goodwill, as goodwill is not amortized. As of February 28, 2013 and November 30, 2012, the net Saneron investment, which represents goodwill, is reflected on the consolidated balance sheets at approximately \$684,000. As of February 28, 2013 and November 30, 2012, management reviewed the Saneron investment to determine if there were any indicators that would imply that the investment was impaired. Based on management's review, there were no indicators of other than temporary impairment and goodwill was not impaired as of February 28, 2013 and November 30, 2012.

For the three months ended February 28, 2013 and February 29, 2012, the Company recorded equity in losses of Saneron operations of approximately \$38,000 and \$39,000, respectively, related to certain stock awards that were granted by Saneron to certain employees, consultants and members of Saneron management who represent owners of Saneron and serve on its board of directors. The Company will continue to record equity in losses of affiliates related to stock compensation expense as this offsets additional paid-in capital and not the investment balance.

As of February 28, 2013 and November 30, 2012, the Company has classified the Company's portion of the value of Company stock held by Saneron of approximately \$485,000 within stockholders' deficit as treasury stock.

In January 2008, the Company announced that it has formalized a research and development agreement with Saneron to develop regenerative therapies utilizing Cryo-Cell's menstrual stem cell technology. Cryo-Cell and Saneron collaborate on research in pre-clinical models for certain neurological diseases and disorders. Under terms of the agreement, the Company provides Saneron with menstrual stem cells along with proprietary methodology associated with the technology. Saneron provides study materials and develops the research methodology for potential therapeutic applications associated with designated pre-clinical applications. Intellectual property resulting from this research collaboration will be jointly owned by the parties.

### **Note 4 Stock Options**

The Company maintains the 2000 Stock Incentive Plan as amended (the 2000 Plan) that has reserved 2,250,000 shares of the Company's common stock for issuance pursuant to stock options or restricted stock. Options issued under the Plan have a term ranging from five to seven years from the date of grant and have a vesting period ranging from immediately upon issuance to three years from the date of grant. The options are exercisable for a period of 90 days after termination. As of February 28, 2013 and November 30, 2012, there were 58,089 and 60,589 shares outstanding under the 2000 Plan, respectively. No further options will be issued under the 2000 Plan.

**Table of Contents**

The Company also maintains the 2006 Stock Incentive Plan (the "2006 Plan"). The 2006 Plan has reserved 1,000,000 shares of the Company's common stock for issuance pursuant to stock options, restricted stock, stock-appreciation rights (commonly referred to as "SARs") and stock awards (i.e. performance shares and performance units). As of February 28, 2013 and November 30, 2012, there were 759,759 and 762,509 shares outstanding under the 2006 plan, respectively. As of February 28, 2013, there were 142,845 shares available for future issuance under the 2006 Plan.

The Company also maintains the 2012 Equity Incentive Plan (the "2012 Plan") which became effective December 1, 2011 as approved by the Board of Directors and approved by the stockholders at the 2012 Annual Meeting on July 10, 2012. The 2012 Plan reserved 1,500,000 shares of the Company's common stock for issuance pursuant to stock options, restricted stock, stock-appreciation rights (commonly referred to as "SARs") and stock awards (i.e. performance shares and performance units). In May 2012, the Board of Directors approved an amendment to the Plan to increase the number of shares of the Company's common stock reserved for issuance under the 2012 Plan to 2,500,000 shares. As of February 28, 2013 and November 30, 2012, there were 1,000,000 performance options to purchase shares granted under the 2012 plan and 1,500,000 shares available for future issuance.

*Service-based vesting condition options*

The fair value of each option award is estimated on the date of the grant using the Black-Scholes valuation model that uses the assumptions noted in the following table. Expected volatility is based on the historical volatility of the Company's stock over the most recent period commensurate with the expected life of the Company's stock options. The Company uses historical data to estimate option exercise and employee termination within the valuation model. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant. The expected term of options granted to employees is calculated, in accordance with the simplified method for plain vanilla stock options allowed under GAAP. Expected dividends are based on the historical trend of the Company not issuing dividends.

Variables used to determine the fair value of the options granted for the three months ended February 28, 2013 and February 29, 2012 are as follows:

	February 28, 2013	February 29, 2012
<b>Weighted average values:</b>		
Expected dividends	0%	0%
Expected volatility	113.8%	111.5%
Risk free interest rate	.80%	.93%
Expected life	5.0 years	5.8 years

The range of expected volatilities for options issued during the three months ended February 28, 2013 and February 29, 2012 are as follows:

February 28, 2013	February 29, 2012
112.9% - 114.9%	111.3% - 113.3%



**Table of Contents**

Stock option activity for the three months ended February 28, 2013, was as follows:

	Shares	Weighted Average Exercise Price	Weighted Average Remaining Contractual Life (Years)	Aggregate Intrinsic Value
Outstanding at November 30, 2012	1,183,098	\$ 2.15	7.12	\$ 580,730
Granted	8,500	2.09		
Exercised				
Expired/forfeited	(13,750)	1.94		
Outstanding at February 28, 2013	1,177,848	\$ 2.15	6.90	\$ 233,259
Exercisable at February 28, 2013	972,866	\$ 2.12	7.11	\$ 224,577

The weighted average grant date fair value of options granted during the three months ended February 28, 2013 and February 29, 2012 was \$1.68 and \$1.47, respectively.

The aggregate intrinsic value represents the total value of the difference between the Company's closing stock price on the last trading day of the period and the exercise price of the options, multiplied by the number of in-the-money stock options that would have been received by the option holders had all option holders exercised their options on either February 28, 2013 or February 29, 2012, as applicable. The intrinsic value of the Company's stock options changes based on the closing price of the Company's stock.

There were no options exercised during the three months ended February 28, 2013 and February 29, 2012.

Significant option groups exercisable at February 28, 2013 and related price and contractual life information are as follows:

Range of Exercise Prices	Outstanding	Outstanding		Exercisable	
		Weighted Average Remaining Contractual Life (Years)	Weighted Average Exercise Price	Outstanding	Weighted Average Exercise Price
\$0.42 to \$1.00	7,500	2.15	\$ 0.78	7,500	\$ 0.78
\$1.01 to \$ 2.00	529,259	7.57	\$ 1.69	516,763	\$ 1.69
\$2.01 to \$ 3.00	600,500	6.82	\$ 2.50	408,014	\$ 2.58
\$3.01 to \$ 4.00	40,589	0.10	\$ 3.34	40,589	\$ 3.34
	1,177,848	6.90	\$ 2.15	972,866	\$ 2.12

A summary of the status of the Company's non-vested shares as of February 28, 2013, and changes during the three months ended February 28, 2013, is presented below:

Shares	Weighted Average Grant-Date Fair Value
--------	--

Edgar Filing: CRYO CELL INTERNATIONAL INC - Form 10-Q

Non-vested at November 30, 2012	251,403	\$	1.77
Granted	8,500		1.68
Vested	(49,089)		1.50
Forfeited	(5,832)		1.96
Non-vested at February 28, 2013	204,982	\$	1.83

**Table of Contents**

As of February 28, 2013 there was approximately \$204,000 of total unrecognized compensation cost related to non-vested service related share-based compensation arrangements granted under the 2000 Plan, 2006 Plan and the 2012 Plan. The cost is expected to be recognized over a weighted-average period of 1.5 years as of February 28, 2013. The total fair value of shares vested during the three months ended February 28, 2013 was approximately \$73,500.

*Performance and market-based vesting condition options*

There were no performance-based or market-based vesting condition options granted during the three months ended February 28, 2013. Variables used to determine the fair value of options with performance-based and market-based vesting conditions granted during the three months ended February 29, 2012 are as follows:

	February 29, 2012
Weighted average values:	
Expected dividends	0%
Expected volatility	112.3%
Risk free interest rate	.90%
Expected life	5.5 years

The range of expected volatilities for performance-based and market-condition options issued during the three months ended February 29, 2012 are as follows:

February 29, 2012

111.3% - 113.5%

Stock option activity for options with performance-based and market-based conditions for the three months ended February 28, 2013, was as follows:

	Shares	Weighted Average Exercise Price	Weighted Average Remaining Contractual Life (Years)	Aggregate Intrinsic Value
Outstanding at November 30, 2012	640,000	\$ 1.74	8.83	\$ 511,600
Granted				
Exercised				
Expired/forfeited				
Outstanding at February 28, 2013	640,000	\$ 1.74	8.58	\$ 230,000

Exercisable at February 28, 2013

## **Table of Contents**

The weighted average grant date fair value of performance and market conditions options granted during the three months ended February 29, 2012 was \$1.21.

During the fiscal year ended November 30, 2012, the Company granted 213,334 options that begin to vest based on the achievement of certain share prices of the Company's common stock at certain future dates. For market-based vesting condition options, accounting principles do not require that the market condition be met in order for the compensation cost to be recognized. Fair value of these options has been determined using a binomial model and is being recognized over the requisite service period, regardless if the market condition will be met. As of February 28, 2013 there was approximately \$111,600 of total unrecognized compensation cost related to the non-vested market-based vesting condition options that will be amortized over three years.

The remaining 426,666 options granted to executives and consultants during the fiscal year ended November 30, 2012 require certain performance targets to be met before vesting can occur. Management has deemed these performance targets to be improbable as of February 28, 2013 and November 30, 2012 and thus no compensation cost has been recognized through these dates. The Company will reevaluate the probability of achieving these targets on a quarterly basis, and adjust compensation expense accordingly. As of February 28, 2013 and November 30, 2012 there was approximately \$616,000 of total unrecognized compensation cost related to the non-vested performance-based vesting condition options. If the performance conditions are not achieved by a certain date as specified in each option agreement, no compensation expense associated with these performance based options will be recognized. Total unrecognized compensation cost may fluctuate from quarter to quarter as performance based options issued to consultants are marked to market over the requisite service period.

## **Note 5 License Agreements**

The Company has entered into licensing agreements with certain investors in various international markets in an attempt to capitalize on the Company's technology. The investors typically pay a licensing fee to receive Company marketing programs, technology and know-how in a selected area. The licensing agreement may also give the investor the right to sell sub-license agreements. As part of the accounting for the up-front license revenue, revenue from the up-front license fee is recognized based on such factors as when the payment is due, collectability and when all material services or conditions relating to the sale have been substantially performed based on the terms of the agreement.

The Company enters into two types of licensing agreements and in both types, the Company earns revenue on the initial license fees. Under the technology agreements, the Company earns processing and storage royalties from the affiliates that process in their own facility. Under the marketing agreements, the Company earns processing and storage revenues from affiliates that store specimens in the Company's facility in Oldsmar, Florida.

## **Technology Agreements**

The Company has entered into definitive License and Royalty Agreements with Cryo-Cell de Mexico ( Mexico ) and Asia Cryo-Cell Private Limited to establish and market its umbilical cord blood program in Mexico and India, respectively.

## **Table of Contents**

The Company has entered into definitive License and Royalty Agreements with Asia Cryo-Cell Private Limited and S-Evans Bio-Sciences, Inc. to establish and market its menstrual stem cell program in India and China, respectively.

On August 19, 2011, the Company received notification from Mexico that it was terminating the license agreement effective immediately due to an alleged breach of the license agreement. On October 17, 2011, the Company and Mexico entered into an amendment to the license agreement whereby the termination has been revoked and Mexico will pay the Company \$1,863,000 in 37 monthly installments of \$50,000 beginning on October 17, 2011 with a final payment of \$13,000. Mexico will have no other continuing obligations to the Company for royalties or other license payments and the agreement will be effectively terminated once the entire \$1,863,000 has been received. Mexico also has the option to pay off the amount early with no penalties. The amendment is expected to result in a reduction of licensee income in future periods.

As of February 28, 2013 and November 30, 2012, the Company recorded a receivable of \$976,454 and \$1,115,505, respectively, and deferred revenue of \$970,245 and \$1,104,623, respectively, in the accompanying consolidated balance sheets. Accounts receivable is calculated using the present value of all of the monthly installments using a discount rate that reflects both the risk-free rate at the inception of the contract and the contract period. In accordance with the agreement, the Company received three installments of \$50,000 during the first quarter of 2013 and the first quarter of 2012, which is reflected in the consolidated statement of operations as of February 28, 2013 and February 29, 2012 as licensee and interest income. The installment amounts that are to be received and recognized within the next twelve months have been classified as short-term as Accounts Receivable in the accompanying consolidated balance sheets.

## **Marketing Agreements**

The Company has definitive license agreements to market both the Company's umbilical cord blood and menstrual stem cell programs in Costa Rica, El Salvador, Guatemala, Honduras, Nicaragua, Panama and Pakistan. In October 2012, the Company sent notice of termination to the Company's Venezuelan affiliate, which represents Venezuela, Chile, Colombia and Peru, for failure to meet its payment obligation in accordance with the contract. Subsequent to the notice of termination, payment was received for outstanding processing and storage fees due from Venezuela. The Company is in the process of discussing a new agreement. The Company continues to accept umbilical cord blood and menstrual stem cell specimens to be processed and stored during the negotiations. In December 2012, the Company sent notice of termination to the Company's affiliate in Ecuador for failure to meet its payment obligation in accordance with the contract. Subsequent to the notice of termination, payment was received for outstanding processing and storage fees due from Ecuador. The Company is in the process of discussing a new agreement. The Company continues to accept umbilical cord blood and menstrual stem cell specimens to be processed and stored during the negotiations.

Processing and storage revenues from specimens originating in territories that store at the Company's facility in Oldsmar, Florida totaled \$374,221 and \$406,385 for the three months ended February 28, 2013 and February 29, 2012, respectively, and are reflected in processing and storage fees in the accompanying consolidated statements of operations.

**Table of Contents**

The following table details the initial license fees for the technology and marketing agreements and processing and storage royalties earned for the technology agreements for the three months ended February 28, 2013 and February 29, 2012. The initial license fees and processing and storage royalties are reflected in licensee income in the accompanying consolidated statements of operations.

	For the three months ended					
	February 28, 2013			February 29, 2012		
	License Fee	Process and Storage Royalties	Total	License Fee	Process and Storage Royalties	Total
India	\$	\$ 169,412	\$ 169,412	\$	\$ 169,412	\$ 169,412
Mexico		154,122	154,122		167,330	167,330
Nicaragua				5,000		5,000
Total	\$	\$ 323,534	\$ 323,534	\$ 5,000	\$ 336,742	\$ 341,742

**Note 6 Proxy Contest**

In August 2007, Mr. David Portnoy (the plaintiff) brought an action against the Company and its directors in Delaware Chancery Court in New Castle County. The plaintiff alleged breaches of fiduciary duties in connection with the Company's 2007 Annual Meeting and requested declaratory and injunctive relief relating to the election of directors at that meeting. On January 22, 2008, the Court issued an order under which the Company was required to hold a special meeting of stockholders for the election of directors on March 4, 2008; and the order provided that directors who sat on the Company's Board of Directors prior to the 2007 Annual Meeting would continue in office until the special meeting. The order provided that the members of the management slate pay their own proxy solicitation costs in connection with the special meeting; any costs to the Company of holding the special meeting; and the costs of a special master to preside over the special meeting. On March 4, 2008, the Company held a Special Meeting of Stockholders, at which the directors nominated in management's proxy statement dated February 11, 2008 were elected by the Company's stockholders.

On May 9, 2011, the Company was notified that Mr. David Portnoy nominated five directors to the Company's board of directors to compete with the Company's board of directors at the 2011 Annual Meeting. Mr. Portnoy conducted his own solicitation of the Company's stockholders in favor of his nominees. In light of the activities associated with the 2007 annual meeting, on June 6, 2011, Mr. Portnoy brought another action seeking declaratory relief in the Delaware Chancery Court before the same judge that had ruled on the 2007 action.

On August 24, 2011, the Board of Directors of the Company approved funding a Grantor trust to escrow the amounts that may become payable to certain members of senior management (the Participants) under their respective Employment Agreements as a result of a Change in Control (as that term is defined in the respective employment agreements as a majority change in the Company's Board of Directors). The trustee of the Grantor Trust Agreement is Wells Fargo Bank, National Association (Trustee). On August 25, 2011, the Company transferred \$2,500,000 to the Trust which is reflected as restricted cash in the accompanying consolidated balance sheets as of February 28, 2013 and November 30, 2012. The trust became irrevocable upon the Change in Control on August 25, 2011. The Company has no power to direct the Trustee to return the funds to the Company. The funds will be returned to the Company when the Trustee is satisfied that the obligations have been satisfied per any agreed upon terms. If the Company becomes insolvent, the Trustee will cease payments of benefits to the Participants and the cash will revert to the Company. Upon written approval of all Participants, the Company may terminate the trust. During the three months ended February 28, 2013 and February 29, 2012, \$8,434 and \$34,903, respectively, in legal fees were paid from the trust on behalf of one of the Participants. As of February 28, 2013 and November 30, 2012 the balance in the trust is \$2,343,413 and \$2,372,439, respectively, which is reflected in the accompanying consolidated balance sheets as of February 28, 2013 and November 30, 2012. As of February 28, 2013, one of the three Participants continues to be employed by the Company.

**Table of Contents**

On August 24, 2011, the Board of Directors of the Company approved the acceleration of any unvested stock options and the extension of the exercise period of such options for options held by the Board of Directors and the Participants in the event of a Change in Control. On November 23, 2011, the Board of Directors of the Company revoked the previous resolution.

The Company held its 2011 Annual Meeting of Stockholders on August 25, 2011 ( the Annual Meeting ). The final voting results were certified by the Inspector of Elections on August 30, 2011. Mr. Portnoy's nominees were elected to the Company's Board of Directors triggering a complete change in the Company's Board of Directors.

On August 30, 2011, the newly elected Board of Directors of the Company terminated its Chief Executive Officer and former Chairman of the Board of Directors, Mercedes Walton, for cause. In accordance with Ms. Walton's employment agreement dated August 15, 2005, as amended July 16, 2007, Ms. Walton could be entitled to severance in the amount up to \$950,000 related to lost salary, bonuses and benefits. In addition, the Company could be required to pay all reasonable legal fees and expenses incurred by Ms. Walton as a result of the termination, as well as outplacement services. The Company has recorded an accrual of approximately \$950,000 associated with the agreement which is reflected as an accrued expense in the accompanying consolidated balance sheets as of February 28, 2013 and November 30, 2012. The Company believes that Ms. Walton was terminated for cause as defined in her employment agreement and therefore, the Company believes that Ms. Walton has not earned the right to this severance and intends to defend itself against the agreement.

On August 31, 2011 the Company's Board of Directors approved the reimbursement by the Company to the Portnoy Group of its costs associated with the litigation resulting from the 2007 Annual Meeting and the 2011 Annual Meeting's proxy contest. The total costs reimbursed during the fourth quarter of fiscal 2011 were approximately \$528,000.

On May 30, 2012, the Company received a Nomination Solicitation Notice nominating six individuals to the Company's board of directors to compete with the Company's board of directors at the 2012 Annual Meeting. Pursuant to the Co-CEOs employment agreements, upon receipt by the Company of this Nomination Solicitation Notice, as defined in the Company's Bylaws, all of the service-based vesting condition options that were issued to the Co-CEOs vested. Due to the immediate vesting of the options issued to the Co-CEOs, approximately \$700,000 was recorded as stock option compensation expense during the second quarter of fiscal 2012.

**Note 7 Legal Proceedings**

On May 26, 2011, a complaint for monetary damages was served against the Company. The complaint did not specify the amount claimed, other than stating that it is more than \$75,000 which is the jurisdictional amount of the court in which the complaint was filed. At this time, it is not possible for the Company to estimate the loss or the range of possible loss, due to the current early stage of the litigation, the meaningful legal uncertainties associated with the claim and the fact that the complaint did not specify the amount of damages sought. No amounts have been accrued as of February 28, 2013 and November 30, 2012. The Company believes it has meritorious defenses to the claims included in this complaint and intends to vigorously defend itself; however, the ultimate resolution of this complaint is uncertain at this time. A trial has been scheduled for September 3, 2013.

On October 25, 2011, Mercedes Walton, the Company's former chief executive officer, filed a demand for arbitration with the American Arbitration Association. See Note 6.

**Table of Contents**

In addition, from time to time the Company is subject to proceedings, lawsuits, contract disputes and other claims in the normal course of its business. The Company believes that the ultimate resolution of current matters should not have a material adverse effect on the Company's business, consolidated financial position or results of operations. It is possible, however, that there could be an unfavorable ultimate outcome for or resolution which could be material to the Company's results of operations for a particular quarterly reporting period. Litigation is inherently uncertain and there can be no assurance that the Company will prevail. The Company does not include an estimate of legal fees and other related defense costs in its estimate of loss contingencies.

**Note 8 Cancellation of Revenue Sharing Agreements**

On December 6, 2011, the Company entered into an Asset Purchase Agreement with Bio-Stor canceling the Bio-Stor Revenue Sharing Agreement (RSA). Pursuant to the terms of the Asset Purchase Agreement, on December 6, 2011, the Company made a one-time, lump-sum payment in the amount of \$2.3 million to Bio-Stor, and Bio-Stor sold, assigned, conveyed, transferred, and delivered to the Company all of its rights, interest and title in the RSA. The payment amount of \$2.3 million was offset by the carrying amount of the short-term liability related to Bio-Stor in the amount of \$900,000 and an accrued expense in the amount of \$172,610 to reflect the extinguishment of revenue sharing agreements in the amount of \$1,227,390 for the three months ended February 29, 2012.



---

**Table of Contents**

**Note 9 Share Repurchase Plan**

In December 2011, the Company's Board of Directors authorized management at its discretion to repurchase up to one million (1,000,000) shares of the Company's outstanding common stock. On June 6, 2012, the Board of Directors of the Company increased the number of shares of the Company's outstanding common stock that management is authorized to repurchase to up to three million (3,000,000). The repurchases must be effectuated through open market purchases, privately negotiated block trades, unsolicited negotiated transactions, and/or pursuant to any trading plan that may be adopted in accordance with Rule 10b5-1 of the Securities and Exchange Commission or in such other manner as will comply with the provisions of the Securities Exchange Act of 1934.

As of February 28, 2013, the Company had repurchased a total of 899,502 shares of the Company's common stock at an average price of \$2.17 per share through open market and privately negotiated transactions. The Company purchased 107,128 and 415,117 shares of the Company's common stock during the first quarters of fiscal 2013 and 2012, respectively, at an average price of \$2.31 per share and \$1.82 per share, respectively.

The repurchased shares will be held as treasury stock at cost and have been removed from common shares outstanding as of February 28, 2013 and November 30, 2012. As of February 28, 2013 and November 30, 2012, 1,049,602 and 942,474 shares, respectively, were held as treasury stock, which include 150,100 and 150,100 shares, respectively, which is the Company's portion of the value of the Company stock held by Saneron.

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.  
Forward Looking Statements**

This Form 10-Q, press releases and certain information provided periodically in writing or orally by the Company's officers or its agents may contain statements which constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. The terms Cryo-Cell International, Inc., Cryo-Cell, Company, we, our, us refer to Cryo-Cell International, Inc. The words expect, anticipate, believe, goal, strategy, plan, intend, estimate and similar expressions, if used, are intended to specifically identify forward-looking statements. Those statements appear in a number of places in this Form 10-Q and in other places, and include statements regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things:

- (i) our future performance and operating results;
- (ii) our future operating plans;
- (iii) our liquidity and capital resources; and
- (iv) our financial condition, accounting policies and management judgments.

Investors and prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. The factors that might cause such differences include, among others, the risk factors set forth in Part I, Item 1A. Risk Factors of our most recent Annual Report on Form 10-K and the following:

- (i) any adverse effect or limitations caused by recent increases in government regulation of stem cell storage facilities;

Edgar Filing: CRYO CELL INTERNATIONAL INC - Form 10-Q

- (ii) any increased competition in our business including increasing competition from public cord blood banks particularly in overseas markets but also in the U.S.;

**Table of Contents**

- (iii) any decrease or slowdown in the number of people seeking to store umbilical cord blood stem cells or decrease in the number of people paying annual storage fees;
- (iv) market acceptance of our menstrual stem cell service will require publication of scientific studies, consumer awareness, and the development of new therapies from the menstrual stem cell technology, none of which are certain;
- (v) any new services relating to other types of stem cells that have not yet been offered commercially, and there is no assurance that other stem cell services will be launched or will gain market acceptance;
- (vi) any adverse impacts on revenue or operating margins due to the costs associated with increased growth in our business, including the possibility of unanticipated costs relating to the operation of our facility and costs relating to the commercial launch of the placental stem cell service offering or any other new types of stem cells;
- (vii) any unique risks posed by our international activities, including but not limited to local business laws or practices that diminish our affiliates' ability to effectively compete in their local markets;
- (viii) any technological or medical breakthroughs that would render our business of stem cell preservation obsolete;
- (ix) any material failure or malfunction in our storage facilities; or any natural disaster or act of terrorism that adversely affects stored specimens;
- (x) any adverse results to our prospects, financial condition or reputation arising from any material failure or compromise of our information systems;
- (xi) the costs associated with defending or prosecuting litigation matters, particularly including litigation related to intellectual property, litigation resulting from the termination of the former Chairman and CEO, and any material adverse result from such matters;
- (xii) current market, business and economic conditions in general and in our industry in particular;
- (xiii) the success of our licensing agreements and their ability to provide us with royalty fees;
- (xiv) any difficulties and increased expense in enforcing our international licensing agreements;
- (xv) any adverse performance by or relations with any of our licensees;
- (xvi) any inability to enter into new licensing arrangements including arrangements with non-refundable upfront fees;

Edgar Filing: CRYO CELL INTERNATIONAL INC - Form 10-Q

- (xvii) any inability to realize cost savings as a result of recent acquisitions;
  
- (xviii) any inability to realize a return on an investment;

**Table of Contents**

- (xix) any increased U.S. income tax expense as a result of inability to utilize or exhaustion of net operating losses;
- (xx) any adverse impact on our revenues as a result of greater emphasis in the future on the promotion of our menstrual stem cell service and any shifting of our marketing dollars towards our menstrual stem cell service;
- (xxi) any adverse impact on our revenues and operating margins as a result of discounting of our services in order to generate new business in tough economic times where consumers are selective with discretionary spending;
- (xxii) the success of our global expansion initiatives;
- (xxiii) our actual future ownership stake in future therapies emerging from our collaborative research partnerships;
- (xxiv) the ability of our reproductive tissue storage services to generate new revenues;
- (xxv) our ability to minimize our future costs related to R&D initiatives and collaborations and the success of such initiatives and collaborations;
- (xxvi) any inability to successfully identify and consummate strategic acquisitions;
- (xxvii) any inability to realize benefits from any strategic acquisitions;
- (xxviii) the costs associated with proxy contests and its impact on our business and
- (xxix) other factors many of which are beyond our control.

We undertake no obligation to publicly update or revise the forward-looking statements made in this Form 10-Q to reflect events or circumstances after the date of this Form 10-Q or to reflect the occurrence of unanticipated events.

Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. Cryo-Cell International, Inc. undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof. Readers should carefully review the risk factors described in other documents the Company files from time to time with the Securities and Exchange Commission, including the Annual Report on Form 10-K filed by the Company and any Current Reports on Form 8-K filed by the Company.

**Overview**

The Company is engaged in cellular processing and cryogenic storage, with a current focus on the collection and preservation of umbilical cord blood stem cells for family use. The Company's principal sources of revenues are service fees for cord blood processing and preservation for new customers and recurring annual storage fees. Effective February 1, 2012, the Company charges fees of \$2,074 to new clients for the collection kit, processing and testing and return medical courier service, with discounts in the case of multiple children from the same family and in other circumstances. The Company currently charges an annual storage fee of \$125 for new clients; storage fees for existing customers depend on the contracts with such customers. The Company also offers a one-time payment plan, where the client is charged \$3,949 less discounts in the case of multiple children from the same family and in other circumstances. The one-time plan includes the collection kit, processing and testing, return medical courier service and 21 years of pre-paid storage fees. The Company also receives other income from licensing fees and royalties

from global affiliates.

In recent years, the Company has expanded its research and development activities to develop technologies related to stem cells harvested from sources beyond umbilical cord blood stem cells. In 2006, the Company discovered technology related to menstrual stem cells. During 2007, much of the Company's research and development activities focused on the development of proprietary technology related to maternal placental stem cells (MPSCs). In November 2007, the Company announced the commercial launch of the menstrual stem cell service related to this patent-pending technology. The Company continues to conduct independently-funded research and development activities through a vast network of research collaboration partners.

## **Table of Contents**

In August 2011, there was a change in control of the board of directors. Subsequent to this change, the Company is refocusing its efforts on the Company's umbilical cord blood and cord tissue business while continuing to develop the menstrual stem cell technology.

During the three months ended February 28, 2013, the Company's revenues increased 10% as compared to the same period in 2012. The Company reported net income of approximately \$244,000, or \$0.02 per basic common share for the three months ended February 28, 2013 compared to a net loss of approximately (\$1,700,000) or (\$0.15) per basic common share for the same period in 2012. The increase in net income for the three months ended February 28, 2013 principally resulted from the 10% increase in revenues and a 15% decrease in selling, general and administrative expenses. This was partially offset by a 25% increase in cost of sales. During the three months ended February 29, 2012, the cancellation of the Bio-Stor Revenue Sharing Agreement resulted in a loss from extinguishment of revenue sharing agreement in the amount of approximately \$1,200,000.

At February 28, 2013, the Company had cash and cash equivalents of \$2,859,056. The Company's cash increased by approximately \$182,000 during the first three months of fiscal 2013, primarily as a result of approximately \$506,000 provided by operations which was partially offset by approximately \$250,000 used for the stock repurchase plan pursuant to which the Company repurchased 107,128 shares of the Company's common stock during the three months ended February 28, 2013. As of February 28, 2013, the Company had no long-term indebtedness.

## **Results of Operations**

**Revenues.** Revenues for the three months ended February 28, 2013 were \$4,600,087 as compared to \$4,178,589 for the same period in 2012, a 10% increase. The increase in revenue was primarily attributable to an 11% increase in processing and storage fees, which was partially offset by a 5% decrease in licensee income.

*Processing and Storage Fees.* The increase in processing and storage fee revenue is primarily attributable to an increase in specimens processed of 12% and a 4% increase in recurring annual storage fee revenue.

*Licensee Income.* Licensee income for the three months ended February 28, 2013, was \$323,534 as compared to \$341,742 for the 2012 period. Licensee income for the three months ended February 28, 2013 consisted of \$323,534 in royalty income earned on the processing and storage of specimens in geographical areas where the Company has license agreements. Licensee income for the three months ended February 29, 2012 consisted of \$336,742 in royalty income earned on the processing and storage of specimens in geographical areas where the Company has license agreements. The remaining licensee income related to an installment payment of a non-refundable up-front license fee from the licensee of the Company's umbilical cord blood program in Nicaragua.

**Cost of Sales.** Cost of sales for the three months ended February 28, 2013 was \$1,279,813 as compared to \$1,026,903 for the same period in 2012, representing a 25% increase. Cost of sales was 30% and 27% of processing and storage fee revenue for the three months ended February 28, 2013 and February 28, 2012, respectively. Cost of sales includes wages and supplies associated with process enhancements to the existing production procedures and quality systems in the processing of cord blood specimens at the Company's facility in Oldsmar, Florida and depreciation expense of approximately \$54,000 for the three months ended February 28, 2013 and February 29, 2012.

## **Table of Contents**

***Selling, General and Administrative Expenses.*** Selling, general and administrative expenses for the three months ended February 28, 2013 were \$2,695,278 as compared to \$3,160,797 for the 2012 period representing a 15% decrease. These expenses are primarily comprised of expenses for consumer advertising, salaries and wages for personnel and professional fees. The decrease in selling, general and administrative expenses is primarily due to a decrease of approximately \$313,000 or 22% in sales and marketing due to Company's new sales initiatives, a decrease of approximately \$169,000 or 65% in stock option expense and a decrease of approximately \$77,000 or 24% in professional services.

***Research, Development and Related Engineering Expenses.*** Research, development and related engineering expenses for the three months ended February 28, 2013 were \$10,921 as compared to \$14,579 for the three months ended February 29, 2012. The expenses for each period primarily relate to the implementation of the Company's cord tissue service and the continued commercialization of the Company's menstrual stem cell technology, which was launched in November 2007.

***Depreciation and Amortization.*** Depreciation and Amortization (not included in Cost of Sales) for the three months ended February 28, 2013 was \$51,014 compared to \$56,255 for the 2012 period. The decrease was caused by a portion of the Company's property and equipment becoming fully depreciated during fiscal 2012.

***Extinguishment of Revenue Sharing Agreement.*** On December 6, 2011, the Company entered into an Asset Purchase Agreement with Bio-Stor canceling the Bio-Stor Revenue Sharing Agreement (RSA). Pursuant to the terms of the Asset Purchase Agreement, on December 6, 2011, the Company made a one-time, lump-sum payment in the amount of \$2.3 million to Bio-Stor, and Bio-Stor sold, assigned, conveyed, transferred, and delivered to the Company all of its rights, interest and title in the RSA. The payment amount of \$2.3 million was offset by the carrying amount of the short-term liability related to Bio-Stor in the amount of \$900,000 and an accrued expense in the amount of \$172,610 to reflect the extinguishment of revenue sharing agreement in the amount of \$1,227,390 for the three months ended February 29, 2012.

***Interest Expense.*** Interest expense during the three months ended February 28, 2013, was \$250,538 compared to \$299,165 during the prior year period. The decrease in interest expense is a result of the Company entering into Asset Purchase Agreements with certain RSA's which cancelled these RSA's during fiscal 2012. Interest expense is mainly comprised of payments made to the other parties to the Company's revenue sharing agreements based on the Company's storage revenue.

***Equity in Losses of Affiliate.*** Equity in losses of affiliate was \$38,450 for the three months ended February 28, 2013, compared to \$38,832 for the 2012 period. Equity in losses of affiliate for the three months ended February 28, 2013 and February 29, 2012, consists solely of amounts related to compensation expense for stock option awards that were granted by Saneron to certain consultants and employees.

***Income Taxes.*** Deferred tax assets and liabilities are measured using enacted tax rates expected to be recovered or settled. The ultimate realization of our deferred tax assets depends upon generating sufficient future taxable income prior to the expiration of the tax attributes. In assessing the need for a valuation allowance, we must project future levels of taxable income. This assessment requires significant judgment. We examine the evidence related to the recent history of tax losses, the economic conditions in which we operate and our forecasts and projections to make that determination.

The Company records foreign income taxes withheld from installment payments of non-refundable up-front license fees and royalty income earned on the processing and storage of cord blood stem cell specimens in geographic areas where the Company has license agreements. The Company



## **Table of Contents**

recorded approximately \$42,000 and \$57,000 for the three months ended February 28, 2013 and February 29, 2012, respectively, of foreign income tax expense, which is included in income tax expense in the accompanying consolidated statements of operations. The decrease in foreign tax expense is attributable to the decrease in royalties recognized during the period ended February 28, 2013 compared to February 29, 2012.

There was no U.S. income tax expense for the three months ended February 28, 2013 and for the same period in 2012. The Company did not record income tax expense during the first quarters of 2013 and 2012 due to the utilization of net operating losses and foreign tax credit carryforwards, which were not previously benefited in the Company's financial statements.

## **Liquidity and Capital Resources**

Through February 28, 2013, the Company's principal source of cash has been from sales of its umbilical cord blood program to customers, the sale of license agreements and royalties from licensees. The Company does not expect a change in its principal source of cash flow.

At February 28, 2013, the Company had cash and cash equivalents of \$2,859,056 as compared to \$2,677,382 at November 30, 2012. The increase in cash and cash equivalents during the three months ended February 28, 2013 was primarily attributable to the following:

Net cash provided by operating activities for the three months ended February 28, 2013 was \$505,675, which was primarily attributable to the Company's operating results.

Net cash provided by operating activities for the three months ended February 29, 2012 was \$157,907, which was primarily attributable to the Company's operating results.

Net cash used in investing activities for the three months ended February 28, 2013 was \$76,956, which was primarily attributable to the purchases of property and equipment.

Net cash provided by investing activities for the three months ended February 29, 2012 was \$910,582, which was primarily attributable to the sale of marketable securities which was offset by the purchase of property and equipment and the investment in patents.

Net cash used by financing activities for the three months ended February 28, 2013 was \$247,045 which was attributable to the stock repurchase plan pursuant to which the Company has repurchased 107,128 shares of the Company's common stock.

Net cash used by financing activities for the three months ended February 29, 2012 was \$3,053,511 which was primarily attributable to the cancellation of the Bio-Stor Revenue Sharing Agreement and the stock repurchase plan pursuant to which the Company has repurchased 415,117 shares of the Company's common stock.

The Company does not have a line of credit.

The Company anticipates making discretionary capital expenditures of approximately \$750,000 over the next twelve months for software enhancements and purchases of property and equipment. The Company anticipates funding future property and equipment purchases with cash-on-hand and cash flows from future operations.

The Company anticipates that its cash and cash equivalents, marketable securities and cash flows from future operations will be sufficient to fund its known cash needs for at least the next 12 months.

## **Table of Contents**

Cash flows from operations will depend primarily upon increasing revenues from sales of its umbilical cord blood and cord tissue cellular storage services and the menstrual stem cell service, and managing discretionary expenses. If expected increases in revenues are not realized, or if expenses are higher than anticipated, the Company may be required to reduce or defer cash expenditures or otherwise manage its cash resources during the next 12 months so that they are sufficient to meet the Company's cash needs for that period. In addition, the Company may consider seeking equity or debt financing if deemed appropriate for its plan of operations, and if such financing can be obtained on acceptable terms. There is no assurance that any reductions in expenditures, if necessary, will not have an adverse effect on the Company's business operations, including sales activities and the development of new services and technology.

## **Critical Accounting Policies**

This discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make judgments, estimates, and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and disclosures of contingent assets and liabilities. For a full discussion of our accounting policies please refer to Note 1 to the Consolidated Financial Statements included in our 2012 Annual Report on Form 10-K filed with the SEC. Our most critical accounting policies and estimates include: recognition of revenue and the related allowance for doubtful accounts, stock-based compensation, income taxes and license and revenue sharing agreements. We continually evaluate our judgments, estimates and assumptions. We base our estimates on the terms of underlying agreements, historical experience and other factors that we believe are reasonable based on the circumstances, the results of which form our management's basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. There have been no material changes to our critical accounting policies and estimates from the information provided in Item 7, *Management's Discussion and Analysis of Financial Condition and Results of Operations* included in our 2012 Annual Report on Form 10-K.

## **Recently Issued Accounting Pronouncements**

In February 2013, the FASB issued Accounting Standards Update No. 2013-02, *Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income* (ASU 2013-02). This update will require companies to present information about amounts reclassified out of accumulated other comprehensive income and their corresponding effect on net income in one place and reference the amounts to the related footnote disclosures. Current accounting standards present this information in different places throughout the financial statements. ASU 2013-02 is effective for interim and annual periods beginning after December 15, 2012, with early adoption permitted. The adoption of ASU 2013-02 will only impact disclosure requirements and will not have any effect on the Company's consolidated financial statements or on its financial condition.

**Table of Contents**

**Off-Balance Sheet Arrangements**

The Company has no off-balance sheet arrangements that have or are reasonable likely to have a current or future effect on its financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

**Item 3. Quantitative and Qualitative Disclosures About Market Risk.**

Not applicable.

**Item 4. Controls and Procedures**

**Evaluation of Disclosure Controls and Procedures**

Based on their most recent review, as of the end of the period covered by this report, the Company's principal executive officer and principal financial officer have concluded that the Company's disclosure controls and procedures are effective, and that information required to be disclosed by the

## **Table of Contents**

Company in the reports that it files or submits under the Securities Exchange Act of 1934, as amended, is accumulated and communicated to the Company's management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure and are effective to ensure that such information is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms.

### **Changes in Internal Control Over Financial Reporting**

There were no changes in the Company's internal controls over financial reporting during the three months ended February 28, 2013 that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

### **Limitations on the Effectiveness of Controls**

Our management, including our co-CEOs and CFO, does not expect that our disclosure controls and internal controls will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management or board override of the control.

The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

### **CEO and CFO Certifications**

Appearing as exhibits 31.1, 31.2 and 31.3 to this report there are Certifications of the Co-CEOs and the CFO. The Certifications are required in accordance with Section 302 of the Sarbanes-Oxley Act of 2002 (the Section 302 Certifications). This Item of this report is the information concerning the evaluation referred to in the Section 302 Certifications and this information should be read in conjunction with the Section 302 Certifications for a more complete understanding of the topics presented.

## **PART II - OTHER INFORMATION**

### **ITEM 1. LEGAL PROCEEDINGS**

On May 26, 2011, a complaint for monetary damages was served against the Company. The complaint did not specify the amount claimed, other than stating that it is more than \$75,000 which is the jurisdictional amount of the court in which the complaint was filed. At this time, it is not possible for the Company to estimate the loss or the range of possible loss, due to the current early stage of the litigation, the meaningful legal uncertainties associated with the claim and the fact that the complaint did not specify the amount of damages sought. No amounts have been accrued as of February 28, 2013 and November 30, 2012. The Company believes it has meritorious defenses to the claims included in this complaint and intends to vigorously defend itself; however, the ultimate resolution of this complaint is uncertain at this time. A trial has been scheduled for September 3, 2013.

**Table of Contents**

On October 25, 2011, Mercedes Walton, the Company's former chief executive officer, filed a demand for arbitration with the American Arbitration Association. Ms. Walton is claiming breach of her employment agreement and defamation. Ms. Walton is seeking arbitration costs, attorneys' fees, interest, compensatory, punitive and liquidated damages, as well as injunctive and declaratory relief in the amount of \$5,000,000 of which potentially \$1,000,000 would be covered by the Company's insurance policy. On August 30, 2011, the Board of Directors of the Company terminated its Chief Executive Officer and former Chairman of the Board of Directors, Ms. Walton, for cause. In accordance with Ms. Walton's employment agreement dated August 15, 2005, as amended July 16, 2007, Ms. Walton could be entitled to severance in the amount up to \$950,000 related to lost salary, bonuses and benefits. In addition, the Company could be required to pay all reasonable legal fees and expenses incurred by Ms. Walton as a result of the termination, as well as outplacement services. The Company has recorded an accrual of approximately \$950,000 as of February 28, 2013 and November 30, 2012, associated with the agreement. On August 24, 2011, the Board of Directors of the Company approved funding a Grantor trust to escrow the amounts that may become payable to Mercedes Walton under her respective Employment Agreement as a result of a Change in Control (as that term is defined in the respective employment agreements as a majority change in the Company's Board of Directors). The Company believes that Ms. Walton was terminated for cause and therefore, the Company believes that Ms. Walton has not earned the right to this severance and intends to defend itself against the agreement. A hearing took place during the week of February 4, 2013 and reconvened on March 19, 2013. Post-trial briefs are due May 1, 2013.

In addition, from time to time the Company is subject to proceedings, lawsuits, contract disputes and other claims in the normal course of its business. The Company believes that the ultimate resolution of current matters should not have a material adverse effect on the Company's business, consolidated financial position or results of operations. It is possible, however, that there could be an unfavorable ultimate outcome for or resolution which could be material to the Company's results of operations for a particular quarterly reporting period. Litigation is inherently uncertain and there can be no assurance that the Company will prevail. The Company does not include an estimate of legal fees and other related defense costs in its estimate of loss contingencies.

**ITEM 1A. RISK FACTORS**

In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended November 30, 2012, which could materially affect our business, financial condition or future results. The risks described in our Annual Report on Form 10-K are not the only risks we face.

**Table of Contents****ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS****ISSUER PURCHASE OF EQUITY SECURITIES**

Period	Total Number of Shares Purchased	Average Price Paid per Share	Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs	Maximum Number (or Approximate Dollar Value) of Shares that May Yet Be Purchased Under the Plans or Programs
December 1 - 31, 2012	87,868	\$ 2.33	87,868	2,119,758
January 1 - 31, 2013	17,450	\$ 2.24	17,450	2,102,308
February 1 - 28, 2013	1,810	\$ 2.01	1,810	2,100,498

**ITEM 3. DEFAULTS UPON SENIOR SECURITIES**

None.

**ITEM 4. MINE SAFETY DISCLOSURES**

Not Applicable.

**ITEM 5. OTHER INFORMATION**

None.

**Table of Contents**

**ITEM 6. EXHIBITS**

(a) Exhibits

31.1	Certification of Co-CEO Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 <i>(filed herewith)</i> .
31.2	Certification of Co-CEO Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 <i>(filed herewith)</i> .
31.3	Certification of CFO Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 <i>(filed herewith)</i> .
32.1	Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema Document
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	XBRL Taxonomy Extension Label Linkbase Document
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document

**Table of Contents**

**SIGNATURES**

In accordance with Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Cryo-Cell International, Inc.

/s/ DAVID PORTNOY

David Portnoy  
Co-Chief Executive Officer

Cryo-Cell International, Inc.

/s/ MARK PORTNOY  
Co-Chief Executive Officer

Cryo-Cell International, Inc.

/s/ JILL TAYMANS

Jill M. Taymans  
Vice President, Finance, Chief Financial Officer

Date: April 15, 2013